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INTRODUCTION
The frequency of double valve replacement [DVR; concomi-
tant mitral valve (MV) and aortic valve (AV) replacement] re-
mains low (3% to 14%), compared with isolated valve surgery 
for aortic and mitral pathologies.1,2 Although a reduction in 
right-ventricular pressure or volume overload after concomi-
tant left-sided valve surgery is expected to reduce the progres-
sion of tricuspid regurgitation (TR),3 TR does not always re-
gress after adequate correction of underlying lesions4,5 and 
can even develop de novo postoperatively. The prevention of 
late TR is clinically important, because this condition adverse-
ly affects long-term mortality and morbidity, and surgical cor-
rection of TR after left-sided valve surgery is associated with 
disappointingly high mortality and morbidity.6-8
Significant late-onset TR is unfortunately common after 
DVR;9,10 however, the underlying factors remain undefined. 
Long-term follow-up studies have evaluated the incidence and 
risk factors associated with late TR development in organic TR 
patients or only in those with rheumatic valvular disease or 
mitral valvular lesions.5,11 Moreover, in the context of DVR, small-
sized aortic prostheses are often chosen to prevent interference 
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Purpose: Significant late-onset tricuspid regurgitation (TR) is unfortunately common after double valve replacement (DVR); 
however, its underlying factors remain undefined. We evaluated the effect of aortic patient-prosthesis mismatch (PPM) on late-
onset TR and clinical outcomes after DVR. 
Materials and Methods: Of the 2392 consecutive patients who underwent aortic valve replacement between January 1990 and 
May 2014 at our institution, we retrospectively studied 462 patients who underwent DVR (excluding concomitant tricuspid valvu-
lar annuloplasty or replacement). Survival and freedom from grade >3 TR were compared between PPM (n=152) and non-PPM 
(n=310) groups using the Kaplan-Meier method. 
Results: Although the overall survival rates were similar between the two groups at 5 and 10 years (95%, 91% vs. 96%, 93%, 
p=0.412), grade >3 TR-free survival was significantly lower in the PPM group (98%, 91% vs. 99%, 95%, p=0.014). Small body-sur-
face area, atrial fibrillation, PPM, and subaortic pannus were risk factors for TR progression. However, aortic prosthesis size and 
trans-valvular pressure gradient were not significant factors for either TR progression or overall survival.  
Conclusion: Aortic PPM in DVR, regardless of mitral prosthesis size, was associated with late TR progression, but was not signifi-
cantly correlated with overall survival. Therefore, we recommend careful echocardiographic follow-up for the early detection of 
TR progression in patients with aortic PPM in DVR.  
Key Words:  Heart valve prosthesis implantation, double valve replacement, tricuspid valve regurgitation, patient-prosthesis mismatch
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from mitral prostheses that are implanted earlier in the opera-
tion. In Asians especially, smaller aortic prostheses are com-
monly chosen in DVR cases for the previous reasons. Based 
on the hypothesis that the use of aortic prostheses of smaller 
size in DVR might induce severe patient-prosthesis mismatch 
(PPM) at the aortic position and adversely influence the right-
heart hemodynamics, leading to TR development, this study 
investigated the effect of aortic prosthesis PPM on late-onset 
TR and clinical outcomes in DVR.
MATERIALS AND METHODS
Study population
Among 2392 consecutive patients who underwent MV or AV 
surgery between January 1990 and May 2014 at Severance Car-
diovascular Hospital, Yonsei University College of Medicine, 
751 patients who had undergone DVR, with or without tricus-
pid valve surgery, were retrospectively reviewed. Excluding 
those who had undergone concomitant tricuspid repair or re-
placement surgery, coronary artery bypass grafting, and aorta 
surgery, a total of 462 patients were finally included in our study. 
Patients with unclear or missing operative records were also 
excluded. 
Baseline data collection
The patients’ hospital records and our surgical database were 
reviewed for the following: age at surgery, sex, body weight, 
heart rhythm, type of surgery, and history of prior cardiac sur-
gery. A preoperative echocardiographic examination had been 
performed in all patients by a skilled and experienced cardiol-
ogist. The left-ventricular end-systolic diameter (mm) and left-
ventricular end-diastolic diameter (mm), left-ventricular ejec-
tion fraction (LVEF, %), and valvular functions were compre-
hensively evaluated. The etiologies of valvular disease were 
confirmed based on surgical observations and pathologic fi-
ndings. Follow-up echocardiographic examinations were per-
formed, focusing on the trans-aortic valve pressure gradient 
(PG, mm Hg). The study protocol was approved by the Institu-
tional Review Board of Severance Hospital, Yonsei University 
College of Medicine. Individual patient consent was waived, 
because this study did not interfere with patient treatment and 
because the database was designed so that individual patients 
could not be identified. All baseline and clinical characteristics 
were obtained from the medical records of the patients.
Echocardiographic examinations 
Clinical and echocardiographic assessments were performed 
prior to DVR and 12–60 months after operation. The presence 
of TR and its severity were assessed using multiple transtho-
racic windows. The maximal TR jet area in any echocardio-
graphic view was used to semi-quantitatively estimate the TR 
grade using a standard color Doppler technique. The TR grade 
was classified as none (0), trivial (1), mild (2), moderate (3), or 
severe (4) in each patient.12 To simplify the statistical analysis, 
significant TR was defined as moderate or severe in degree. 
The latest significant TR was regarded as the primary outcome 
of the follow-up period. The trans-aortic PG was measured by 
the continuous-wave Doppler method with sampling from mul-
tiple echocardiographic windows, using imaging and non-
imaging Doppler probes. The LV dimensions were measured 
in the two-dimensional guided M-mode.13 The LVEF was deter-
mined by a combination of the Teichholz formula14 and visual 
assessment of LV function from multiple echocardiographic 
windows. 
Definition of PPM
The effective orifice area (EOA, cm2) for each type and size of 
prosthesis was obtained from the literature or from the manu-
facturers,15 and the parameter of choice validated to identify 
PPM was the indexed EOA (IEOA), which is the EOA of the pr-
osthesis being implanted indexed to the patient’s body surface 
area (BSA). We classified PPM as not clinically significant (i.e., 
mild or absent) if the IEOA was >0.85 cm2/m2, as moderate if it 
was >0.65 and ≤0.85 cm2/m2, and as severe if it was ≤0.65 cm2/m2.16 
To validate the cutoff IEOA value of 0.85, we constructed re-
ceiver operating characteristic curves, which indicated a cut-
off value of IEOA=0.88 for inducing PPM (Fig. 1). To test the 
Fig. 1. ROC curve of aortic prosthesis size analysis to obtain the cutoff size 
value for inducing PPM. IEOA, indexed effective orifice area; TR, tricus-
pid regurgitation; ROC, receiver operating characteristic; PPM, patient-
prosthesis mismatch.
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hypothesis that PPM is a strong correlation factor for TR pro-
gression, the patients were accordingly divided into PPM (IEOA 
≤0.85; n=152) and non-PPM (IEOA >0.85; n=310) groups un-
der the presumption that the cutoff IEOA value for defining 
PPM was reasonable (0.85≈0.88).
Statistical analysis
Continuous variables were expressed as mean±SD and cate-
gorical variables as percentages. The primary event outcomes 
were defined as significant TR (Gr. 3, 4) or repeat tricuspid 
valve surgery (valvuloplasty or replacement) after surgery, and 
the secondary event outcome was overall (cumulative) mortal-
ity. Significant-TR-free survival rates (%) were plotted using the 
Kaplan-Meier method, and comparisons were made between 
the groups with PPM and non-PPM aortic prosthetics using 
the log-rank test. Cox hazard regression analysis including all 
significant parameters identified by uni- and multivariate anal-
ysis was undertaken to identify parameters independently as-
sociated with the presence of significant TR and late mortality 
after surgery. 
All reported p values were two-sided, and a value of p<0.05 
was considered statistically significant. SPSS version 18.0 (IBM 
Corp., Armonk, NY, USA) and MedCalc (MedCalc Software, 
Ostend, Belgium) were used for the statistical analyses.
RESULTS
Baseline characteristics
The baseline characteristics of the 462 study subjects are sum-
marized in Table 1. The mean follow-up duration was 128±80 
months. Preoperative electrocardiograms showed atrial fibril-
lation (AF) in 235 (51%) patients; 234 (50.6%) patients were 
female; the mean BSA was 1.7±0.4 (kg/m2); and 220 (47.6%) pa-
tients had New York Heart Association class 3 or 4 congestive 
heart failure. Mechanical and tissue DVR were performed in 414 
patients and 48 patients, respectively. As a large portion of the 
patients had rheumatic pathology (85%), mechanical prosthe-
sis was used in a majority of patients. The tissue valve replace-
ment group showed a higher incidence of significant PPM, 
compared with the mechanical valve group (28% vs. 71%). Se-
vere mitral stenosis (MS) and aortic stenosis (AS) patients com-
prised 330, while combined MS and regurgitation with AS ac-
counted for 53 (Table 2). The mean aortic and mitral prosthesis 
sizes were 21.2±1.7 mm and 28.5±1.7 mm, respectively. 
 
Clinical and echocardiographic features after DVR 
Aortic position PPM occurred in 152 patients (32.9%). The peak 
and mean values of the trans-aortic valvular pressure gradient 
(TAPG peak and mean, respectively; mm Hg) were significantly 
higher in the PPM group (42.3±20.9 vs. 30.5±17.3, p<0.001 and 
Table 1. Patient Pre- and Post-Operative Data 
Variables PPM group (n=152) No PPM group (n=310) p value
Age (yr) 49.9±14.8 49.7±11.0 0.842
Female sex 77 (62.1) 157 (46.4) <0.001
Hypertension 13 (10.5) 54 (15.9) 0.183
Diabetes mellitus 7 (5.6) 20 (5.9) 1.000
Preoperative EF (%) 62.1±10.1 61.1±11.5 0.378
BSA (kg/m2) 1.7±0.5 1.8±0.4 0.136
Preoperative AF 61 (49.2) 174 (51.5) 0.732
Rheumatic disease 101 (81.5) 294 (86.9) 0.143
NYHA (3 or 4) 37 (29.8) 183 (54.1) <0.001
Mechanical prosthesis 118 (77.2) 296 (95.5) <0.001
Perioperative data
Aortic prosthesis size (mm) 20.0±1.3 21.6±1.7 <0.001
Mitral prosthesis size (mm) 28.4±1.9 28.6±1.7  0.257
Postoperative data
TAPG (peak, mm Hg) 42.3±20.9 30.5±17.3 <0.001
TAPG (mean, mm Hg) 24.4±12.8 17.3±10.6 <0.001
The change of RVSP (mm Hg) 10.55±11.65 9.81±12.73 0.531
LVMI (g/m2) 126.5±52.3 133.4±32.5 0.432
LV mass reduction (%) 54.1 56.3 0.592
Subaortic pannus formation 18 (14.5) 40 (11.8) 0.434
Paravalvular leakage 5 (2.7) 18 (5.3) 0.808
EOA 1.2±0.2 1.8±0.3 <0.001
EF, ejection fraction; BSA, body surface area; AF, atrial fibrillation; NYHA, New York Heart Association; TAPG, trans-aortic valvular pressure gradient; LVMI, left 
ventricular mass index; LV, left ventricular; EOA, effective orifice area; RVSP, right ventricular systolic pressure.
Data are presented as a mean±SD or n (%).
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Table 2. Preoperative Underlying Valve Diseases at Time of Surgery
MV disease
AV disease
Total
AS AR ASR
MS 330   2 15 347
MR   21 13 11   45
MSR   53   1 16   70
Total 404 16 42 462
MV, mitral valve; MR, mitral regurgitation; MS, mitral stenosis; MSR, mitral 
stenosis and regurgitation; AV, aortic valve; AS, aortic stenosis; AR, aortic re-
gurgitation; ASR, aortic stenosis and regurgitation.
Fig. 2. PPM incidence according to aortic prosthesis size. PPM, patient-
prosthesis mismatch; IEOA, indexed effective orifice area.
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Fig. 3. Overall cumulative survival rates for PPM and non-PPM groups. 
PPM, patient-prosthesis mismatch.
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24.4±12.8 vs. 17.3±10.6, p<0.001, respectively) at the latest post-
operative follow-up. Subaortic pannus formation was observed 
in 58 patients (12.6%) [the presence of subaortic pannus was 
established by cardiac computed tomography in the case of 
high-transvalvular pressure gradient (TVPG) patients] and pa-
ravalvular leakage in any position (aortic or mitral) was ob-
served in 23 patients (4.9%); 52 (11.3%) patients progressed to 
significant TR. PPM occurred most frequently with the 19-mm 
aortic prosthesis (75/152, 49.3%), regardless of mitral prosthe-
sis size (Fig. 2). 
Clinical events and late-onset TR, overall mortality 
risk analysis
Of the 462 study subjects, 61 patients died from any cause 
during follow-up (PPM: n=23, 15.1%; non-PPM: n=38, 12.3%). 
The overall survival rate was not significantly different between 
the groups (1, 5, and 10 years: 100%, 96%, 93% in PPM group 
vs. 99%, 95%, 91% in non-PPM group, p=0.41) (Fig. 3). Signifi-
cant TR (grade 3 or 4) developed in 52 patients (11.3%) by the 
latest follow-up: 33 (21.7%) in the PPM group and 19 (6.2%) in 
the non-PPM group. The rate of freedom from significant TR 
was significantly different between the two groups: the PPM 
group showed significantly lower event-free survival than the 
non-PPM group according to Kaplan-Meier survival analysis 
(1, 5, and 10 years: 100%, 99%, 91% in PPM vs. 100%, 99%, 95% 
in non-PPM, p=0.014) (Fig. 4). To identify independent factors 
for the development of late-onset significant TR, we performed 
multivariate forward Cox hazard regression analysis using 
clinical and echocardiographic parameters, including age, 
sex, preoperative LV function (LVEF, %), presence of preoper-
ative AF, aortic and mitral prosthesis size (mm), sub-aortic 
pannus formation, and TAPG at latest follow-up (mm Hg). This 
analysis identified the following as multivariate independent 
determinants of late TR development: small BSA [hazard ratio 
(HR), 0.31; 95% confidence interval (CI), 0.18–0.54; p=0.012], 
presence of preoperative AF (HR, 3.08; 95% CI, 1.34–7.09; 
p=0.008), PPM (IEOA ≤0.85 cm2/m2) (HR, 1.69; 95% CI, 0.91–
3.17; p=0.046), and subaortic pannus formation (HR, 2.14, 95% 
CI, 1.06–4.31; p=0.033). In the analysis of overall survival, the 
meaningful multivariate determinants were age (HR, 1.05; 95% 
CI, 1.02–1.08; p=0.010) and subaortic pannus formation (HR, 
4.12, 95% CI, 1.39–12.15; p=0.010) (Table 3).
DISCUSSION
In this study, late significant TR developed more often in pa-
tients with aortic PPM than in those without, regardless of aor-
tic prosthesis size (from 19 mm to 25 mm). Despite the large 
number of published reports on the association between left-
sided valvular surgery and TR progression, none had clearly 
established the possible underlying mechanisms of TR pro-
gression after DVR. The incidence of significant TR after left-
heart valve surgery varies among reports, because of differ-
ences among study group compositions, follow-up durations, 
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Fig. 4. TR-progression-free survival rates for PPM and non-PPM groups. 
TR, tricuspid regurgitation; PPM, patient-prosthesis mismatch.
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Table 3. Cox Hazard Regression Analysis for Late TR Progression and Overall Survival in the DVR Population 
TR (Gr. 3, 4) Overall survival
Univariate Multivariate Univariate Multivariate
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age (yr) 1.03 (1.00–1.06) 0.023 1.02 (0.48–8.32) 0.113 1.07 (1.05–1.09) 0.001 1.05 (1.02–1.08)  0.010
Female sex 2.47 (1.36–4.47) 0.008 1.10 (0.48–2.55) 0.821 0.93 (0.56–1.54) 0.782
BSA (kg/m2) 0.31 (0.18–0.54) 0.012 0.71 (0.32–1.57) 0.049 0.61 (0.36–1.02) 0.058
Hypertension   2.78 (0.38–20.52) 0.314 1.11 (0.44–2.85) 0.823
Valve pathology (rheumatic) 1.91 (1.46–1.87) 0.372
Ejection fraction 1.01 (0.99–1.03) 0.261 0.98 (0.96–1.00) 0.081
Preoperative AF 3.24 (1.52–6.92) 0.009 3.08 (1.34–7.09) 0.008 2.06 (1.02–4.18) 0.047 2.13 (1.03–4.40) 0.042
Aortic prosthesis size 0.62 (0.51–0.75) 0.003 0.60 (0.43–0.83) 0.002 1.04 (0.89–1.19) 0.634
Mitral prosthesis size 0.77 (0.66–0.91) 0.004 1.06 (0.85–1.32) 0.578 0.82 (0.71–0.95) 0.012 0.79 (0.67–0.94) 0.010
Mechanical type  4.19 (1.42-12.34) 0.013 0.49 (0.12 -2.05) 0.334 0.19 (0.09–0.38) 0.001 0.23 (0.09–0.57) 0.004
IEOA 0.17 (0.03–0.95) 0.045 0.74 (0.17–3.17) 0.684
PPM (yes vs. no) 1.95 (1.12–3.40) 0.021 1.69 (0.91–3.17) 0.046 0.80 (0.48–1.36) 0.408
TAPG (peak, mm Hg) 1.02 (1.01–1.03) 0.008 1.03 (0.98–1.09) 0.196 1.00 (0.98–1.01) 0.649
TAPG (mean, mm Hg) 1.03 (1.02–1.05) 0.008 0.94 (0.87–1.03) 0.201 1.00 (0.97–1.02) 0.542
Pannus formation 
  (subaortic portion)
4.58 (2.63–7.97) 0.001 2.14 (1.06–4.31) 0.033 0.33 (0.12–0.92) 0.032 4.12 (1.39–12.15) 0.010
Paravalvular leakage 1.24 (0.39–4.00) 0.721 0.77 (0.24–2.46) 0.661
TR, tricuspid regurgitation; DVR, double valve replacement; BSA, body surface area; AF, atrial fibrillation; IEOA, indexed effective orifice area; PPM, patient-pros-
thesis mismatch; TAPG, trans-aortic valvular pressure gradient; HR, hazard ratio; CI, confidence interval.
and definitions of significant TR,11,17,18 with late severe TR re-
ported in 14–43% of patients after MV surgery and in 7–27% of 
patients with left-sided valve surgery, including AV surgery 
alone. The incidence of significant TR after left-heart valve 
surgery also varies depending on the etiology of MV disease, 
from rheumatic to degenerative. Song, et al.19 reported that 
rheumatic etiology was strongly associated with the develop-
ment of late significant TR. Pancarditis associated with the pro-
gression of rheumatic fever can result in increased right-ven-
tricular susceptibility both to subclinical damage and to pro-
gressive dysfunction and geometric change after exposure to 
hemodynamic changes provoked by left-sided valvular lesions.20 
In this study, despite the high proportion of patients (83%) with 
rheumatic valvular pathology, this factor showed no associa-
tion with late significant TR progression in univariate analysis 
(HR, 1.91, 95% CI, 0.46–1.87; p=0.372). 
The sex difference in the incidence of late TR also needs 
further clarification. In a study with long-term follow-up (11.3 
years) of 65 patients with rheumatic heart disease and signifi-
cant preoperative organic TR, the incidence of late TR was 67%, 
and female sex was an independent predictor of TR develop-
ment.5 Song, et al.19 also posited that female sex was an indepen-
dent predictor of TR progression because of the confounding 
effect of a relatively high prevalence of rheumatic involvement 
of the MV. These results may suggest that female sex, as op-
posed to male sex, is associated with the presence of a small 
aorta or AV annulus, which results in the choice of a small aor-
tic prosthesis. However, in the present study, female sex was 
only a predictor of late TR progression in the univariate analy-
sis and lost its significance as a multivariate risk factor. Only 
small BSA, regardless of sex, was a strong predictor for late TR 
progression. In the context of DVR, the aortic prosthesis size 
can also be affected by an implanted mitral prosthesis, and in 
fact, we selected smaller-sized prostheses to aid safe implan-
tation in the aortic position. Therefore, small BSA, regardless of 
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sex, might be a key factor for the selection of the aortic pros-
thesis in DVR. 
Preoperative AF is also a well-known significant risk factor 
for late TR progression. A previous study found a 16% inci-
dence of late significant TR during an 8.2-year follow-up of 174 
patients after MV surgery, with AF as an independent predic-
tor.11 The potential association between AF and late TR was also 
supported by the finding that a concomitant maze procedure 
was beneficial for the prevention of late TR.21 In the present 
study, there were 235 cases with preoperative AF, which has 
also been documented as a strong risk factor for late TR pro-
gression (HR, 5.31, 95% CI, 2.02–11.12; p<0.001). 
The TVPG is also regarded as an important causal factor for 
late TR progression. High TVPG at an aortic position can in-
duce left-ventricular hypertrophic changes, which appear to 
be associated with gradually increasing left-atrial pressure, ev-
entually resulting in right-heart structural changes manifest-
ing as TR. High TVPG at an aortic position may also underlie 
pannus formation, which has been linked to inflammatory re-
actions against a foreign body or to turbulent transvalvular blood 
flow. However, in the present study, high TVPG (both peak and 
mean) was not itself a predicting factor (HR, 1.03, 95% CI, 0.96–
1.67; p=0.391), although resulting pannus formation was a st-
rong predictor of late-onset TR (HR, 4.86, 95% CI, 2.13–11.12; p< 
0.001). These results suggest that high TVPG may not always be 
correlated with pannus formation and that high TVPG without 
pannus might not induce late TR. This might be related with 
the nature of PPM and pannus formation. Though pannus for-
mation is a progressive process, it might not be an issue before 
it induces significant narrowing. When pannus creates a cer-
tain level of narrowing, the acute pressure load can have a sud-
den impact on the right side of the heart and TR. Unlike this, 
the increase of TVPG from simple valvular degeneration is a 
gradual process with sufficient time for the right heart to adapt 
to the increased pressure. Yoshikawa, et al.22 suggested that 
small Asian female patients might have a greater tendency to 
form pannus than Western patients, but did not explore an as-
sociation with late TR progression. 
In terms of the effects of small-sized aortic prostheses on 
late-onset TR, Jeong suggested that a high TVPG might be re-
lated to the progression to late TR in 132 patients (mean age 
54±13 years) who underwent AVR using ATS valves.23 However, 
that study only included ATS valves and a relatively small study 
population, and did not evaluate subaortic pannus. In our study, 
TVPG was not a multivariate predictor of late TR, although it 
was significant in univariate analysis.  
Cox hazard analysis of aortic PPM showed a statistically st-
rong correlation with late TR progression (HR, 1.95, 95% CI, 
1.12–3.40; p=0.029). From this result, we suggest that taking 
steps to avoid aortic PPM where possible would reduce the 
risk of TR progression. In our study, smaller aortic prostheses 
were associated with greater PPM incidence, and most cases 
of PPM occurred with 19-mm-sized prostheses (Fig. 2). There-
fore, a careful check for PPM following the manufacturer’s in-
structions, especially when a small size (e.g., 19 mm) is selected, 
would be an important step during DVR to minimize the risk 
of late TR progression, although there was no significant cor-
relation herein between PPM and the cumulative survival rate 
(HR, 0.80, 95% CI, 0.48–1.46; p=0.412). Size itself did not show 
significant correlation with TR incidence, although a rather 
larger size showed more TR onset in our analysis using scatter 
grams (Supplementary Fig. 1, only online). Also in our results, 
tissue valve replacement showed a higher incidence of signifi-
cant PPM than mechanical valves (28% vs. 71%), and it might 
be related with the sex of patients, as tissue valves are pre-
ferred for young female patients with smaller BSA than male 
patients.
Several limitations of this study need to be acknowledged. 
First, the study is limited by its retrospective nature. Second, 
the tricuspid annulus size was not quantified in all cases. Pre-
existing dilatation of the tricuspid annulus in the absence of TR 
may be associated with a higher rate of progression to TR, com-
pared with the normal-annulus population. Third, mitral po-
sition PPM was not considered seriously in this analysis. Actu-
ally, the effect of mitral PPM on late survival is uncertain, and 
estimates of EOA can vary largely among different methods of 
calculation,24 which could have some effect on results. Finally, 
the pathology of most patients was rheumatic; despite its sta-
tistical insignificance as a risk factor according to univariate 
analysis, the progression of rheumatic disease might be con-
siderably different in the study population, compared with the 
general population. Given such differences, the progression 
of TR may have been affected by rheumatic involvement in 
each case. 
In conclusion, this study identified risk factors (small BSA, AF, 
aortic PPM, and pannus at the aortic position) associated with 
progression to significant TR after left-sided DVR. The choice 
of a small aortic prosthesis (≤19 mm) in DVR was associated 
with a higher rate of PPM, which in turn was strongly correlated 
with late TR progression. Therefore, careful follow-up by echo-
cardiography for the detection of TR progression is important 
in patients with small aortic prosthesis implantation in the con-
text of DVR. 
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